Related coverage linked through entity extraction aliases.
Aug 05, 2026
Meta-analysis of 24 trials found chemoimmunotherapy improved survival in PD-L1-high advanced NSCLC. PPIs and antibiotics were linked to worse durvalumab outcomes, and a chronotherapy trial was retracted.
Aug 04, 2026
An armored GPC3-directed CAR T-cell therapy showed manageable safety and antitumor activity in refractory HCC, with 44.4% objective responses and 14.2-month median overall survival in a first-in-human trial.
Jul 29, 2026
Candel initiated the Phase 3 AURORA trial of aglatimagene in NSCLC and plans a Q4 2026 BLA in localized prostate cancer, with a potential 2027 launch. The company also appointed a Chief Commercial Officer.
Jul 09, 2026
New research shows obesity-associated immune checkpoint inhibitor efficacy depends on the diet–gut microbiome axis rather than metabolic dysfunction. Human-to-mouse fecal microbiota transplants from high-BMI donors enhanced ICI efficacy, while a review outlines obesity-related inflammation's role in lung cancer immunotherapy outcomes and biomarkers.
Aug 06, 2026
New research links gut microbiome composition to cancer immunotherapy outcomes. A 674-patient study showed gut bacteria predict melanoma recurrence with up to 94% accuracy, while other studies identified specific microbes influencing treatment response and resistance in melanoma and liver cancer.
Jul 06, 2026
Hematologic cancer survivors face elevated CVD risk and fourfold higher heart failure risk. Cardiac screening is low among cardiotoxic treatment recipients. A trial found simple risk assessment may suffice.
Aug 08, 2026
Recent studies have uncovered new cancer therapeutic targets and strategies, including self-assembling antibody-drug conjugates, a dual-action metabolic drug, and a BRAF protein structure. Research also advanced on dendritic cell vaccines, the origins of a rare childhood leukemia, and cancer cachexia treatment.
Jul 15, 2026
Four biomarkers—MMR, HER2, PD-L1, and Claudin 18.2—are now validated for advanced esophageal cancer, guiding immunotherapy and targeted treatment decisions. Checkpoint inhibitors show clear benefit in MSI-H and PD-L1-positive subgroups, with long-term survival observed. NCCN guidelines recommend broad testing to personalize therapy.
Jun 18, 2026
Immune checkpoint inhibitors are associated with a significantly lower risk of non-neovascular age-related macular degeneration, while sociodemographic disparities strongly influence diabetic retinopathy screening adherence, according to two separate ophthalmology studies.
May 27, 2026
Three trials show ultra-low-dose checkpoint inhibitors retain efficacy with reduced toxicity and dramatically lower costs. DELII and Patil et al. trials tested low-dose nivolumab in solid tumors and HNSCC; NIVIPIT tested intratumoral low-dose ipilimumab in melanoma.
May 13, 2026
Tumour-infiltrating lymphocyte therapy has shown durable responses in refractory melanoma, including a 31.4% objective response rate in phase II data. The 2024 FDA approval of Lifileucel marked a milestone as regulators in other markets continue reviews.
May 07, 2026
Cancer care is being transformed by targeted therapy, immunotherapy, personalized medicine, and emerging mRNA-based universal cancer vaccines. Advances in immunotherapeutics and cellular therapies are improving survival rates, while an off-the-shelf mRNA vaccine from the University of Florida is already in human trials.
May 04, 2026
A retrospective study found that myocarditis within the first month after immune checkpoint inhibitor initiation was linked to higher mortality risk. The analysis identified 4,635 cases in VigiBase.
May 01, 2026
European biotechs are exploring new immunotherapy targets beyond PD-1/PD-L1, including BTLA, TIGIT, and SLAMF6. Lund University researchers discovered a SLAMF6-mediated immune evasion mechanism. BioNTech and GenMab are advancing next-generation ICIs and bispecific antibodies through strategic partnerships.
Apr 29, 2026
GeoVax is advancing Gedeptin toward a Phase 2 trial in head and neck cancer and has secured an exclusive license from Emory University for Gedeptin-ICI combination technology. The therapy has Orphan Drug Designation for oral and pharyngeal cancers.
Apr 20, 2026
The global cancer monoclonal antibodies market was valued at USD 66.7 billion in 2025 and is expected to reach USD 135.2 billion by 2033. Growth is being driven by targeted therapies, bispecific antibodies, ADCs and checkpoint inhibitors.
Apr 15, 2026
PDS Biotechnology announced positive interim Phase 2 Stage 1 data for PDS01ADC plus HAIP in MSS/pMMR colorectal liver metastases. The trial showed a 77.8% objective response rate and about 85% 24-month survival in 9 patients.
Apr 11, 2026
A Feb. 20, 2026 study in the Journal of Experimental Medicine identified CD8 T cell-derived TNF and TNFR2 signaling as drivers of ICI-related myocarditis in mice. Blocking TNFR2 prevented the inflammatory cycle in the heart.
Apr 11, 2026
A FAERS database analysis identified 13 FDA-approved systemic medications with disproportionately high uveitis reporting signals among 7,301 events from 2003 to 2024. The strongest signals were for cidofovir and rifabutin, and the findings were described as hypothesis-generating rather than causal.
Apr 05, 2026
A rectal cancer study found hypofractionated radiotherapy increased ISG15+MHC-I+ neutrophils with antigen-presenting capabilities. The report linked the effect to IFN-α/NOD1 signaling and improved anti-PD-1 responses in models.
